PMS-GALANTAMINE TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
12-10-2016
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
GALANTAMINE (GALANTAMINE HYDROBROMIDE)
Inapatikana kutoka:
PHARMASCIENCE INC
ATC kanuni:
N06DA04
INN (Jina la Kimataifa):
GALANTAMINE
Kipimo:
8MG
Dawa fomu:
TABLET
Tungo:
GALANTAMINE (GALANTAMINE HYDROBROMIDE) 8MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100
Dawa ya aina:
Prescription
Eneo la matibabu:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0144660002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2010-01-26
Tabia za bidhaa
Page 1 of 53
PRODUCT MONOGRAPH
Pr
PMS-GALANTAMINE
galantamine hydrobromide tablets
4 mg, 8 mg and 12 mg galantamine base
Cholinesterase Inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave, Suite #100
Montreal, Quebec
H4P 2T4
Control #
106278
Date of Preparation:
January 22, 2010
Page 2 of 53
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................3
SUMMARY PRODUCT INFORMATION
...............................................................3
INDICATIONS AND CLINICAL USE
.....................................................................3
CONTRAINDICATIONS
..........................................................................................4
WARNINGS AND PRECAUTIONS
........................................................................4
ADVERSE REACTIONS
..........................................................................................8
DRUG INTERACTIONS
.........................................................................................14
DOSAGE AND ADMINISTRATION
.....................................................................16
OVERDOSAGE
.......................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
...................................................19
STORAGE AND STABILITY
................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................24
PART II SCIENTIFIC INFORMATION
........................................................................25
PHARMACEUTICAL INFORMATION
................................................................25
CLINICAL TRIALS
.................................................................................................26
DETAILED PHARMACOLOGY
............................................................................34
TOXICOLOGY
........................................................................................................35
REFEREN
Soma hati kamili
